Biosimilars Boast Big Savings But Face IP Risks, Report Says
There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association for Accessible...To view the full article, register now.
Already a subscriber? Click here to view full article